All the news Showing 10 of 228 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Sofosbuvir/ledipasvir regimens can cost less per cure than older hepatitis C treatments Liz Highleyman / 20 June 2016 The cost of treating chronic hepatitis C with sofosbuvir/ledipasvir (Harvoni) is lower than the cost of prior interferon-based therapy with first-generation direct-acting antivirals (DAAs), in part because the newer drugs are well ... ABT-493 + ABT-530 cures most hepatitis C patients across genotypes in SURVEYOR studies Liz Highleyman / 03 June 2016 A co-formulation of AbbVie's experimental next-generation direct-acting antiviral agents ABT-493 and ABT-530 was well-tolerated and led to sustained virological response in 97% or more of patients across all hepatitis C virus (HCV) genotypes ... Sofosbuvir/velpatasvir produces high hepatitis C cure rates and subjective improvement in ASTRAL trials Liz Highleyman / 31 May 2016 A co-formulation of Gilead Science's sofosbuvir and its investigational hepatitis C virus (HCV) NS5A inhibitor velpatasvir taken for 12 weeks produced sustained virological response in 95 to 99% of participants across HCV genotypes ... Elbasvir/grazoprevir superior to sofosbuvir and pegylated interferon/ribavirin Michael Carter / 10 May 2016 New research has demonstrated the clear superiority of an oral combination of direct-acting antivirals (DAAs) over a regimen that combines a DAA with pegylated interferon and ribavirin for the treatment of chronic hepatitis ... Investigational combination ABT-493 and ABT-530 works well in patients who did not achieve SVR12 with previous DAA therapy Michael Carter / 26 April 2016 An experimental combination of direct acting antivirals (DAAs) is effective and safe in HCV-genotype-1-infected patients who did not respond to previous DAA therapy, according to research presented to the recent International Liver Congress ... Portugal's roll-out of HCV therapy with DAAs achieves impressive outcomes Michael Carter / 25 April 2016 Roll-out of hepatitis C virus (HCV) therapy using direct-acting antivirals (DAAs) has achieved excellent outcomes in Portugal, data presented to the International Liver Congress in Barcelona shows. Overall, 96% of patients had a ... Adolescents with hepatitis C achieve high cure rates with sofosbuvir/ledipasvir Liz Highleyman / 25 April 2016 Sofosbuvir/ledipasvir (Harvoni) was well tolerated and led to sustained virological response in 97% of adolescents (age 12-17) with chronic hepatitis C, with high cure rates regardless of prior treatment experience or presence ... DAAs achieve excellent outcomes in real-world settings Michael Carter / 21 April 2016 Hepatitis C virus (HCV) therapy with direct-acting antivirals (DAAs) is as effective in real-world settings as it was in clinical trials, according to US research presented to the International Liver Congress in Barcelona ... AbbVie pan-genotypic combination for hepatitis C achieves 97-100% cure rate in genotype 3 Keith Alcorn / 20 April 2016 A new combination of direct-acting antivirals developed by AbbVie is highly effective in curing hepatitis C in people with genotype 3 infection and cirrhosis, results of two phase II studies presented at last ... Novel therapy RG-101 plus antivirals could cure hepatitis C in 4 weeks Liz Highleyman / 20 April 2016 Two injections of RG-101, an experimental drug that targets the micro-RNA miR-122 in liver cells, combined with direct-acting antiviral agents (DAAs) taken for just 4 weeks, led to 12-week post-treatment sustained response in ... ← Prev1...34567...23Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive